June 20, 2013
| Earlier this week, a Forbes commentary
by John Osborn outlined what the Obama administration "really thinks" about the biopharmaceutical industry. It's not flattering. Osborn says much of the problem lies in a "lingering misimpression" of how drugs are developed. Derek Lowe, blogger at In the Pipeline, offers to spell it out
, and highlights his concerns with the administration's stance.